Management of cholangiocarcinoma in the third millennium: time to be guided!

Cholangiocarcinoma (CCA) is a rare but devastating tumor and the second most frequent primary neoplasm of the liver [1]. Despite being considered infrequent, CCA is increasing its prevalence with regard to the less curable intrahepatic form (i-CCA). Diagnosis, management and therapy of CCA remain dismal and incidence and mortality are nearly comparable nowadays. To tackle the relevant clinical gap in therapeutics, an intense preclinical and clinical research effort has been conducted in the last decades.
Source: Digestive and Liver Disease - Category: Gastroenterology Authors: Source Type: research